Amneal Pharmaceuticals - Class A Share Price Today
Amneal Pharmaceuticals - Class A opened at $21.71, in line with its previous close of $21.71. In the last trading session, the stock traded between $21.25 and $22.07. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Amneal Pharmaceuticals - Class A is now worth
$ 412.49
Giving a profit of
$ 312.49 (312.49%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.06%)
Day High
$22.07
Day Low
$21.25
Day Open
$21.71
Prev Close
$21.71
Volume
11,44,541
1W Return
8.72%
1M Return
8.33%
3M Return
26.97%
6M Return
69.77%
1Y Return
81.56%
Fundamentals
Market Cap ($ Mn)
7,560
PE Ratio
35.80
PB Ratio
169.60
PEG Ratio
0.69
ROE
-
ROCE
15.20%
EPS (TTM)
$-0.06
Investment Returns
1 Week
8.72%
1 Month
8.33%
3 Months
26.97%
6 Months
69.77%
9 Months
47.60%
Financials
Quarterly
All values in $ Mn
724.5
Jun 25
784.5
Sep 25
814.3
Dec 25
722.5
Mar 26
796.2
Jun 26
862.7
Sep 26
Updates
5Nov
JP Morgan raises Amneal Pharmaceuticals price target to $25
JP Morgan raises Amneal Pharmaceuticals price target to $25. Analyst Chris Schott maintains Overweight rating on the stock. Price target increased from previous level of $24.
8 days ago
19Sep
Amneal wins FDA approval for lanreotide injection launch
FDA approves Amneal's lanreotide injection 120 mg/0.5 mL prefilled syringe. Product references SOMATULINE Depot with $983 million U.S. annual sales. Launch targets acromegaly GEP-NETs and carcinoid syndrome treatments. Company cites in-house manufacturing as key supply advantage.
1mo ago
4Sep
Amneal Pharmaceuticals files prospectus for sale of up to 28.9 million shares
Amneal Pharmaceuticals filed an SEC prospectus on August 14, 2026. The filing concerns the offer and sale of Class A common stock. Selling stockholders may offer up to 28,942,098 shares.
2mo ago
10Aug
Amneal completes Kashiv acquisition to build integrated biosimilars platform
Amneal Pharmaceuticals has finalized the acquisition of Kashiv BioSciences, merging its commercial strength with Kashiv’s biologics R&D and manufacturing. The deal creates an integrated biosimilars platform targeting $300 billion in global loss-of-exclusivity opportunities over the next decade.
3mo ago
30Jul
Amneal Pharmaceuticals raises FY26 sales and EPS guidance
Amneal Pharmaceuticals upgrades FY2026 adjusted EPS guidance to $0.96-$1.06 and sales outlook to $3.1B-$3.2B, beating analyst estimates of $0.97 and $3.103B. The revisions reflect improved operational confidence.
3mo ago
30Jul
Amneal Pharmaceuticals Q2 Results: EPS beats estimate by 36%
Amneal Pharmaceuticals posted Q2 EPS of $0.30, beating the $0.22 estimate by 36.36% and rising 20% YoY. Sales hit $796.197M, beating the $768.206M estimate and growing 9.82% from $725.000M last year.
